NCT02071459View on ClinicalTrials.gov

Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

January 21, 2014

Primary Completion Date

October 28, 2019

Study Completion Date

October 28, 2019

Conditions
Multiple System Atrophy
Interventions
DRUG

L-Threo DOPS

initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose

DRUG

placebo

initial period (4 weeks) followed by 8 weeks

Trial Locations (13)

13000

Hôpital La Timone, Marseille

21000

CHU de Dijon, Dijon

35033

CHU Pontchaillou, Rennes

44093

Hôpital G. & R. Laennec, Nantes

49933

Centre hospitalier d'Angers, Angers

59037

CHRU de lille, Lille

63000

CHU de Clermont-Ferrand, Clermont-Ferrand

67091

chu de Strasbourg, Strasbourg

75013

Hôpital Pitié-Salpétrière, Paris

76031

CHU de Rouen, Rouen

86021

CHU de Poitiers, Poitiers

87042

CHU de limoges, Limoges

Unknown

CHU bordeaux, Bordeaux

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER

NCT02071459 - Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA | Biotech Hunter | Biotech Hunter